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Abstract: RSV infection is a leading cause of lower respiratory tract infection, especially in High-risk infants with a 
history of prematurity, bronchopulmonary dysplasia (BPD), congenital heart disease (CHD), neuromusculair impairment, 
immunodeficiency, and Down syndrome. Host related risk factors that have been identified to be associated with severe 
RSV related lower respiratory tract infection include young age below 6 months at the beginning of RSV season, multiple 
birth, male sex, low socioeconomic status and parental education, crowded living conditions, young siblings, maternal 
smoking and indoor smoke pollution, malnutrition/small for gestational age, family history of atopy or asthma, low cord 
serum RSV antibody titers, and living at altitude. 
Risk factors increasing the risk of acquisition of RSV have been identified to be birth before and/or during RSV season, 
day care attendance, presence of older siblings in school or day-care, and lack of breast feeding. Some of these risk factors 
are discussed controversially and some of them are found continuously throughout the literature.  
Given the high cost of RSV prophylaxis, especially for the large population of late preterm infants, algorithms and risk 
score systems have been published that could identify high-risk infants for treatment with palivizumab out of this 
gestational age group. Several models reported on an average sensitivity and specificity of 70 percent and, thus, are 
helpful to identify infants at high risk for severe RSV infection and need for prophylaxis with palivizumab. 
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INTRODUCTION 
  Respiratory syncytial virus (RSV) is a leading cause of 
viral lower respiratory tract infections (LRTI) in early 
childhood, causing an estimated 33 Million LRTI in children 
under the age of five, 3.4 million hospitalizations and 
between 66,000-199,000 deaths annually, globally [1]. 
Almost all infants are infected by 2 to 3 years or following 
two RSV seasons [2]. Infection rates peak in infants aged  
up to 3 months. Several hypotheses exist to explain the 
severity of RSV - LRTI during the first few months of life. 
Immunologic processes play an important role, including an 
immune complex reaction Type III occurring in the lung 
between RSV antigen and maternal acquired IgG antibodies 
[3]
 accompanied by a lack of secretory IgA antibodies, a cell 
mediated Type IV reaction in the lung [4] and T-cell 
independent mechanisms implicating macrophages and   
MIP 1 and other chemokines. Additionally the immature 
immune system and the small infant’s airways are important 
factors explaining the severity of RSV disease within the 
first months of life [5]. This review aims to summarize the 
evidence for risk factors associated with severe RSV - LRTI.  
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PATIENT GROUPS AT HIGH RISK FOR SEVERE 
RSV DISEASE 
Prematurity 
  Prematurity goes along with small, immature and 
vulnerable airways, an immature immune system, an 
incomplete transfer of maternal antibodies and an inadequate 
cellular immunity which is necessary for the viral clearance. 
The lung development at 30 weeks gestational age (GA) 
reveals lung volumes being about three times smaller and a 
surface area being about four times smaller compared to term 
infants, whereas air space walls have an increased wall 
thickness by one third of that of term infants [6]. 
  A longitudinal study up to 10 months of chronological 
age by Ballow, et al. [7]. demonstrated that hypogamma- 
globinemia correlated with lower gestational age and 
remained up to 6 months of chronological age in preterm 
infants below 1500 grams. Following discharge from the 
NICU significantly higher incidence of infections, especially 
LRTIs, were observed in preterm infants. Consecutively 
preterm infants were more often rehospitalized compared   
to term infants. However, despite severe hypogamma- 
globinemia none of the preterm infants had bacterial 
infection. Another study by De Sierra, et al. [8]
 revealed that 
RSV- specific antibody titers were lower in premature 
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and preterm infants of  29 weeks GA had RSV- specific 
titers against F and G protein comparable to those of term 
infants.  
  Prematurity also alters the course of RSV infection. 
Prematurely born infants presented more often with apnoea, 
had a higher incidence of atelectasis/infiltrate and hyper- 
inflation on radiographic examination, longer hospital stays, 
a higher physiologic stability index and therapeutic inter- 
vention score and were more likely to receive supplemental 
oxygen, ICU admission, mechanical ventilation and 
parenteral fluid therapy [9]. These findings were confirmed 
by a prospective study including infants younger than 24 
months and being hospitalized for RSV infection [10]   
that revealed remarkable differences regarding length of 
hospital stay and severity of clinical course of disease 
demonstrated by higher LRI scores, more days of oxygen 
requirement and respiratory support between preterm and 
term born infants.  
 Horn, et al. [11] found significant differences regarding 
ICU admission and rate of intubation as well as length of 
hospital stay between preterm born and term born infants 
with the highest resource use in the late preterm infants of  
33 - 35 weeks GA. In this study the rehospitalization rate due 
to RSV virus infection was 3.6%. 
 Stevens,  et al. [12] found a RSV rehospitalization rate of 
7.6% in prematures born <32 weeks’ gestation with the 
highest rate of 13,9% in the subgroup 26 weeks gestational 
age. The IMPACT trial [13] confirmed these findings and 
revealed in infants < 35 weeks’ gestation a rehospitalization 
rate of 8.1% in the placebo arm, in those born between 32-35 
weeks’ gestation this number was even higher (9.8%). 
Carbonell-Estrany, et al. [14] found a rehospitalization rate 
of 9% in infants born 32 weeks of gestation. However there 
were several studies with lower rates like studies by Resch, 
et al. [15]
 that observed a RSV rehospitalization rate of 2.5% 
in premature infants of 29 to 36 weeks gestation´, Law, et al. 
[16] with a rate of 3.6% in infants of 33-35 weeks’ gestation 
and Figueras-Aloy, et al. [17] with
 a rate of 3.7% in infants 
of 33-35 weeks’ gestation. 
  Recent data by Gunville, et al. [18]
  showed again a 
higher rate of 6.6% (18/271) of children aged under 2 years 
born prematurely (<36 weeks’ gestation) and being 
rehospitalized due to RSV disease. In the subgroup analysis 
2.6% were below 32 weeks’ gestation and 4.1% were of 32- 
35 weeks’ gestation.  
  A summary of the data is shown in Table 1.  
Bronchopulmonary Dysplasia (BPD) 
  Ventilated preterm infants, especially those below 1000g 
birth weight, are at high risk for developing BPD. In these 
infants ventilation-induced volutrauma and oxygen toxicity 
as well as pre- and postnatal infections can initiate and 
sustain a pulmonary inflammatory response leading to a 
possible impaired development of the lung [19] Groothuis,  
et al. [20] were the first to study the burden of early 
rehospitalization in a prospective study including 30 infants 
Table 1.  Prematurity and RSV- Related Rehospitalization Rates 
Study Years  Reference No.  Country  Gestational Age  Total No. of Patients  Rehospitalization Rate (No.) 
1995-1996 11  USA <  37  wk 
 32wk 
33-35 wk 
36 wk 
304 3,6%  (11) 
1,3% (4) 
1,6 % (5) 
0,7% (2) 
1992-1996 12  USA <  32  wk 
 26 wk 
27-28 wk 
>28-30 wk 
>30-32 wk 
1029 
165 
171 
240 
453 
7,6% (78) 
13,9% (23) 
9,9% (17) 
7,5% (18) 
4,4% (20) 
1996-1997 13  USA <  35  wk 
32-25 wk 
<32 wk 
1502 8,1% 
9,8% 
11% 
1998-1999 14  Spain   32 wk  584  9% (53) 
1999-2000  15  Austria  < 37 wk  281  2,5% (7) 
2000-2002  16  Canada  33-35 wk  1832  3,6% (66) 
2005-2007  17  Spain  33-35 wk  5441  3,7% (202) 
2006-2007  18  USA   < 36 wk 
< 32 wk 
33-35 wk 
271 6,6%  (18) 
2,6% (7) 
4,1% (11) 146    The Open Microbiology Journal, 2011, Volume 5  Sommer et al. 
< 2 years with BPD receiving home oxygen therapy after 
discharge from the hospital. In this group 11 of 15 
hospitalizations were due to an RSV infection, 36% of the 
infants were admitted to the intensive care unit (ICU) 18% of 
whom required mechanical ventilation. In the PREVENT 
Study [21], a randomized placebo controlled trial on the use 
of intravenous immunoglobulin prophylaxis (RSV- IGIV) in 
preterm infants with and without BPD, 17.4% infants with 
BPD (26/149) were rehospitalized due to proven RSV infection. 
The IMpact- study [22], a randomized, double- blind, placebo 
controlled trial conducted in the United States, Canada and 
the United Kingdom determining the safety and efficiency of 
palivizumab, revealed an RSV- rehospitalisation rate of 
12.8% in infants with BPD, which was reduced to 7.9% 
(39% reduction) in the group having received palivizumab 
prophylaxis. Thereafter several other studies revealed RSV 
hospitalization rates ranging up to 24.4% [11, 14, 23, 24]. 
Stevens, et al. [11] reported in a cohort of 131 infants requiring 
respiratory support beyond 36 weeks postconceptional age 
that 24.4% were rehospitalized due to RSV infection. They 
were also more likely to be admitted with RSV than infants 
with respiratory support up to 36 weeks postconceptional 
age. In the study of Carbonell- Estrany [14] RSV rehospitaliza-
tion rate was 15% in infants with chronic lung disease. In the 
multivariate logistic regression model the higher risk for 
hospital admission in infants with chronic lung disease was a 
significant prognostic variable (p < 0,016).  
 Greenough, et al. [24] reported in retrospective review 
that in a study cohort of 235 neaontes prematurely born 
neonates < 32 weeks’ gestation requiring oxygen beyong 28 
days after birth 19% were readmitted to the hospital due to a 
proven RSV infection. 
  A more recent study from The Munich RSV Study Group 
[25] reported on a rehospitalisation rate of 15.4% in preterm 
infants   35 GA with BPD. In the multivariate logistic 
regression model BPD as well as male sex and day care- 
attendance of siblings yielded statistical significance as an 
independent predictor for RSV rehospitalisation.  
  Another prospective German multicentre study from the 
RSV Paed Study Group [26]
 found RSV hospitalization rates 
of 12.3% (50/ 356) in preterm infants with BPD. The authors 
also reported on a significantly higher proportion of 
nosocomially acquired RSV infections in the BPD group 
(30.8 % vs. 9.8 %, p<0.001). In the univariant analysis the 
criterion premature infant having BPD requiring treatment 
over the last months was significantly associated with a 
complicated clinical course and was significantly and 
independently associated with the combined outcome 
“complicated course of disease” in the multivariate analysis. 
A summary is shown in Table 2.  
Congenital Heart Disease (CHD)  
  Infants with CHD are known to be at increased risk of 
severe illness from RSV infection regarding higher 
morbidity (more complicated clinical course, e.g. need   
for assisted ventilation or longer duration of oxygen 
supplementation) and higher mortality rate that first was 
reported by MacDonald, et al. [27] to be as high as 37%. 
Navas, et al. [28] from the PICNIC Study Group in Canada 
reported on 260 (16.4%) out of 1584 patients with RSV 
infection having underlying cardiac disease. These children 
required oxygen supplement for a significant longer time 
period and had a significantly higher mortalitiy rate (3.4%) 
compared to children without cardiac disease. In a following 
study from the PICNIC Study Group Wang, et al. [29] 
reported on a lower rate of 8.2% (57/689) of children with 
underlying cardiac disease showing a mortality rate of 5.3%.. 
In the Cardiac Trial (1998) [30]
  the use of RSV hyper- 
immune globulin in the prevention of severe RSV infection 
was associated with increased mortality, thus, the newly 
developed humanized monoclonal antibody, palivizumab, 
had to be proven to be safe in this particular population. 
Feltes, et al. (2003) [31] published data of a multicenter, 
randomized, double-blind, placebo-controlled trial of 1287 
children with hemodynamically significant CHD reporting 
on an RSV hospitalization rate of 9.7% (63/648) that was 
impressively reduced by 45% using monthly palivizumab 
prophylaxis. Based on this data an AAP policy statement 
was released in 2003 [32]
 recommending RSV prophylaxis 
with palivizumab for children <24 months with underlying 
hemodynamically significant CHD. This recommendation 
was also outlined in the revised AAP guidelines in 2009 
[33]. The Palivizumab Outcome Registry Group (2008) [34] 
collected data on 1500 children with CDH accounting for 
7.7% of the entire registry cohort of 19548, who received 
Table 2.  Chronic Lung Disease (CLD)/ Bronchopulmonary Dysplasia (BPD) and RSV- Related Rehospitalization Rates 
Study Years  Reference No.  Country  RSV + CLD/BPD (No.)  Total No. of Patients  Mortalitiy Rate (No.) 
1985-1986 20  USA  59%  (16)  30  0% 
1994  21  USA  17,4% (26)  149  1,3% (2) 
1996  22  USA, Canada, UK  12,8% (34)  266  1,0% (5) 
1992-1996 11  USA  7,6%  (78)  1029  0% 
1998-1999  14  Spain  15% (8)  53  1,8% (1) 
1994-1997 24  UK  19%  (45)  235  - 
1998- 1999  25  Germany  15,4% (8)  53  - 
1999-2005  26  Germany  12,3% (50)  356  8,0% (4) Risk Factors for Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection  The Open Microbiology Journal, 2011, Volume 5    147 
RSV prophylaxis with palivizumab over four seasons (2000-
2004). The majority (71%) had acyanotic CDH. Overall, 
only 1,9% exhibited rehospitalization due to laboratory- 
confirmed RSV infection. The hospitalization rate was 
significantly higher for subjects with compared to those 
without diagnosis of CDH (1.9 % vs. 1.2%, p < 0,03), but 
was significantly lower compared to former trials. A recent 
California state-wide study by Chang, et al. (2010) [35]   
on the use of palivizumab in CDH demonstrated a 19% 
reduction rate of RSV related hospitalizations being equal to 
seven fewer RSV hospitalizations per year for patients with 
hemodynamically significant CHD. In a Danish study [36] 
predictors of RSV hospitalization included Down syndrome 
(OR 3.24, 95% CI 1.80 to 5.80), cardiomyopathy (odds ratio 
(OR) 5.84, 95% CI 1.26 to 27.16) and hemodynamically 
significant heart disease (OR 1.53, 95% CI 1.04 to 2.26) by 
multivariate analysis. Predictors for the need of respiratory 
support during RSV hospitalization including supplemental 
oxygen, nasal continuous positive airway pressure or 
mechanical ventilation were young age (relative risk (RR) 
0.47, 95% CI 0.32 to 0.67 per additional year of age) and 
cardiac decompensation (RR 1.81, 95% CI 1.02 to 3.23). 
 Table  3 summarizes rehospitalization rates due to RSV in 
children with CHD.  
Neuromuscular Impairment  
  Another group of infants being at increased risk for 
severe RSV infection are those with neuromuscular 
impairment. Factors predisposing to a more severe course of 
RSV disease in neuromuscular disease include the impaired 
ability to clear secretions from the airways due to ineffective 
cough resulting from respiratory muscle weakness and   
the high prevalence of gastro-oesophageal reflux and 
swallowing dysfunction, which leads to aspiration [37]. 
Several studies have proven the increased morbidity and 
mortality in patients with an underlying neurological 
impairment. Based on these data recommendations for RSV 
prophylaxis in this high risk group have been integrated in 
the AAP guidelines published 2009 [33]. A more detailed 
essay is the subject of another chapter in this supplement.  
Immunodeficiency, Immunosuppression 
  Patients with severe combined immune deficiency 
syndrome and those with acquired immune deficiency 
syndrome appear to be highly susceptible to severe, 
persistent infections due to a variety of microorganisms, of 
which viruses likely are the most common. Infants show 
prolonged viral shedding and increased morbidity and 
mortality rates associated with RSV infection [37]. RSV was 
recognized as a cause of severe disease following bone 
marrow transplantation (BMT). The presence of neutropenia 
and lymphopenia was identified as being risk factors for the 
development of LRTI infections. A phase-1 study among 
adult recipients of hematopoietic stem cell transplantation 
(HSCT) showed that intravenous palivizumab was well 
tolerated among HSCT patients with and without RSV 
infection [38]. In infants a decision analysis model of 
palivizumab prophylaxis to prevent RSV related mortality 
after pediatric BMT revealed a 10% increase in survival in 
infants who had received palivizumab. The absolute survival 
rate increased from 83% to 92% [39]. Hall, et al. (1986) [40] 
described a cohort of immunocompromized children receiving 
anticancer therapy and found prolonged viral shedding as 
well as higher incidences of LRTI and a higher mortality rate 
(15%) compared to immune competent children. Cole et al 
(2001) [41]
 also reported on a common finding of prolonged 
viral shedding in 18 children with cancer and laboratory 
confirmed RSV infection. Mortality related to RSV infection 
was low independent whether or not specific antiviral 
therapy was given. These findings were confirmed by King, 
et al. (1993) [42] in infants with human acquired immuno- 
deficiency syndrome (HIV) and RSV infection. However, a 
more recent study from South Africa [43] found HIV infected 
children being at increased risk of viral LRTI presenting 
more often as viral pneumonia and having a higher mortality 
rate compared to not HIV infected children. Additionally, 
HIV- infected children showed a less seasonal associated 
occurrence of RSV infection than non-infected infants.  
  Overall these data suggest that infants following solid 
organ or HSC transplantation, infants with congenital   
or acquired immunodeficiency and those under immuno- 
suppressive therapy are a possible new target group to for 
RSV prophylaxis with palivizumab.  
  A summary is displayed in Table 4. 
Down Syndrome 
  Down syndrome is the most common chromosomal 
abnormalitiy and due to it´s variability of immunulogic 
impairments and concomitant respiratory patholoy it is 
associated with a high risk of respiratory tract infections. 
Table 3.  Congenital Heart Disease (CHD) and RSV- Related Rehospitalization Rates 
Study Years  Reference No.  Country  RSV + CHD (No.)  Total No. of Patients  Mortality Rate (No.) 
1976- 1980  27  USA  11,8% (27)  229  37% (10) 
1988- 1991  28  Canada  16,4% (260)  1584  3,5% (9) 
1993  29  Canada  8,3% (57)  689  5,3% (3) 
1998- 2002  30  Multicenter  9,7% (63)  648  6,3% (4) 
2000- 2006  36  USA  3,0% (1596)  53207  1,9% (10) 
1996- 2003  37  Denmark  9,7% (313)  3239  none 148    The Open Microbiology Journal, 2011, Volume 5  Sommer et al. 
Bloemers, et al. (2007) [44] reported an incidence of 9,9% in 
children with down syndrome. The rate of hospitalization for 
RSV was lower in children with Down snydrome without 
chronic heart disease (7,6%) than in preterm children with 
Down syndrome (9,4%) or children with Down syndrome 
and significant chronic heart disease (11,9%). Disease 
severity was not different in children with and without 
additional risk factors such as prematurity or chronic heart 
disease. In contrast Hilton, et al. (1999) suspected that 
chronic heart disease does not influence the high admission 
rate to hospital in children with Down syndrome, but seems 
to increase the severity of disease. Kristensen (2009) [36] 
also showed in a multivariante analysis that children with 
Down syndrome had an increased risk of hospitalization of 
RSV infection. A very recent study by Bloemers, et al. 
(2010) [45]
  showed that hospitalization for RSV induced 
respiratory tract infections in children with Down syndrome 
did not significantly increase the risk of long- term airway 
morbidity, whereas in children without Down syndrome the 
reportet association between development of recurrent 
wheezes and severe RSV related respiratory tract infection 
was confirmed. Unexpectantly a high incidence of recurrant 
wheezes in children with Down syndrome, both with and 
without history of RSV related respiratory tract infection, 
was found.  
HOST RELATED RISK FACTORS INCREASING 
SEVERITIY OF RSV INFECTION 
Age < 6 Months at the Beginning of the RSV Season  
  Young age at the beginning of the RSV season is a risk 
factor for both the development of LRTI as well as 
hospitalization due to RSV infection. Several factors play an 
important role including the immature immune system, 
narrow airways and a bias toward a TH2-type response. Law, 
et al. (1998) [46] showed that age below 12 weeks and a GA 
below 37 weeks contributed independently to the severity of 
RSV infection. A review of recent studies of RSV 
hospitalization rates [47] revealed that approximately 10% to 
28% of infants hospitalized with RSV are aged below 6 
weeks, 49% to 70% below 6 months, and 66% to 100% 
below 1 year. The greatest risk factor for hospitalization due 
to RSV infection appears to be the first few months of life 
when they coincide with the first half of the RSV season. 
This data was also confirmed by two Spanish studies from 
the IRIS Group [17, 48] showing that infants with a 
chronological age below 10 weeks at the onset of the RSV 
season were at higher risk for RSV related hospitalization. 
Multiple Birth 
  In a study cohort from Denver between 1993 and 1989 
twins and triplets were reported to have a significantly 
higher risk of sever RSV LRTI and higher rates of   
RSV related hospitalizations compared to matched singletons 
[49]. This finding was confirmed by a study on hospitaliza- 
tion rates in preterm infants aged 29 to 36 weeks by Resch, 
et al. in 2005 [15] that revealed multiple gestation being a 
risk factor for RSV related hospitalization (odds ratio 5,500, 
CI 95% 1.439- 21.028). In the Spanish FLIP and FLIP- 2 
studies [17,48]
 multiple birth was not associated with higher 
rates of RSV related hospitalizations. However, the authors 
did not perform a multivariate regression analysis. 
Male Sex 
  Male sex is known to be a risk factor for severe RSV 
LRTI. An analysis of representative studies over the last 30 
years found the risk ratio of boys to girls being 1.425:1 [47]. 
The reason therefore seems to be of anatomic nature that 
boys have shorter and narrower airways and are more likely 
to develop bronchial obstruction in case of RSV infection. 
Whereas male sex was regarded as a strong and independent 
risk factor for RSV related hospitalization in the Canadian 
PICNIC study [16]
 this finding could not be confirmed by 
the data of the Spanish FLIP study [48].  
Low Socioeconomic Status and Parental Education 
  Less parental education and low socioeconomic status 
have also been reported to be risk factors for RSV infection 
[50]. Only one study from Sweden in 2002 [51]
 examined 
the role of socioeconomic status in a non-individual setting 
in detail showing a positive correlation with the percentage 
of immigrants and per capita income by univariate analysis. 
Several studies [48, 52, 53] however, could not confirm the 
association of less- educated mothers or parents with an 
increased risk for RSV LRTI. In combination with other risk 
factors maternal education was positively correlated with 
RSV related hospitalization in an early epidemiologic study 
from Tucson in 1991 [54]
 . 
Crowded Living Conditions /Siblings 
  Both crowded living conditions and siblings appear to   
be important risk factors for more severe RSV LRTI and 
RSV related hospitalization. Reasons therefore include   
the increased likelihood of exposure to the virus and 
subsequently the increased risk for infection. Many studies 
demonstrated a significant effect of increased numbers of 
Table 4.  Immunosuppression/ Immunodeficiency and RSV- Related Hospitalization Rates 
Study Years  Reference 
No. 
Country  Immunosuppression +  
RSV (No.) 
Total No. of 
Patients 
Underlying Disease 
1974- 1984  41  USA  7,7% (47)  608  Immune compromized (chemotherapy, cortico-steroid 
therapy, immuno-deficiency disease) 
1994- 1998  42  USA  (18)  unknown  Cancer with polychemotherapy 
1990- 1993  43  USA  7,6% (10)  131  HIV 
1997- 1998  44  South Africa  5,3% (23)  433  HIV Risk Factors for Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection  The Open Microbiology Journal, 2011, Volume 5    149 
persons sharing a bedroom on RSV LRTI [47]. This effect 
was increased in families with low maternal education and 
even more in families with low maternal education who had 
not breast-fed their babies. School- and preschool-aged 
siblings carry an increased for the young infant to acquire 
RSV infection. In the Canadian PICNIC study [16] the 
presence of preschool-aged siblings was significantly and 
independently associated with an increased risk for RSV 
related hospitalization, and a weaker association was found 
with the presence of school-aged siblings. Crowding, defined 
as 5 or more people living in one household, was also 
demonstrated to be a significant risk factor for RSV related 
hospitalization. In some contrast the Spanish FLIP study [48]
 
revealed that only school-aged siblings and the presence of 
more than 4 additional residents and visitors at home were 
risk factors significantly associated with RSV related 
hospitalization. In the FLIP-2 study [17] the effect of school- 
aged siblings was confirmed but not crowding by use of the 
same definition. The Munich RSV Study Group [25]
 found 
that siblings at day care attendance significantly augmented 
the risk for RSV related hospitalization. 
Maternal Smoking and Indoor Smoke Pollution 
  Studies on the influence of smoking in the household on 
the risk of bronchiolitis and RSV LRTI associated 
hospitalization are conflicting [47,55]. The Spanish FLIP 
[48]
 and FLIP-2 [17] studies revealed that the presence of 
more than two smokers at home was associated with a higher 
risk of RSV related hospitalization by bivariate analysis. 
Also The Canadian PICNIC- Study [16] reported household 
exposure to cigarette smoke from 2 or more smokers being 
predictive for RSV related hospitalization. The inconsistent 
evidence on the effect of tobacco smoke exposure on RSV 
LRTI needs further evaluation, and hence, the AAP stated 
that the term air pollution better might characterize this risk 
factor [33]. 
Malnutrition/Small for Gestational Age 
  The role of malnutrition has not been studied in 
industrialized nations. The only existing studies looking at 
these risk factors were carried out in developing countries. 
All of them conclude that RSV was less frequently 
diagnosed in malnourished compared to well-nourished 
children. Thus, malnutrition has not been proven to be a risk 
factor for the development of RSV LRTI. The suspected 
reason for that phenomenon might be that a lower immune 
response provides protection against severe RSV disease 
[47]. Although low birth weight is recognized as a risk   
factor for severe RSV disease the role of intrauterine   
growth restriction has only been examined in the Canadian 
PICNIC- Study [16] being an independent risk factor for 
hospitalization for RSV infection. However, intrauterine 
growth restriction was found to be a risk for death due to 
RSV disease in developing countries [47].  
Family History of Atopy of Asthma 
  The association of RSV infection with a family history of 
allergic disorders is discussed controversial. On the one hand 
RSV is a major cause of recurrent wheezing and “asthma” 
during the following years after an first severe RSV LRTI, 
on the other hand a disposition to asthma causing recurrent 
wheezing is also a cause of debate. In the Canadian PICNIC- 
study [16]
  a
  history of eczema in a first degree family 
member was found to be an independent protective factor for 
RSV hospitalization. However, no association was found for 
family history wheezing or any other allergic disorder. Data 
from the Spanish FLIP-2- study [17] confirmed these 
findings showing that a family history of wheezing did not 
reach statistical significance. In the previous FLIP- study 
[48] however, the history of wheezing in the family was 
found to be of statistical significance, whereas the interaction 
between a history of asthma or eczema in the family did not 
reach statistical significance in the multivariate logistic 
regression analysis.  
Low cord Serum Antibody Titers 
  High titers of maternally derived RSV neutralizing 
antibodies are inversely associated with the incidence of 
acute RSV LRI during the first six months of life. In preterm 
infants incomplete maternally antibody transfer has been 
implicated to increase the risk for severe RSV infection [56]. 
RSV peak activity during winter epidemics appear to be 
associated with decreased herd immunity in the population, 
especially among mothers. In case of high maternal antibody 
titers during the latter part of the RSV season, infants born 
during this period might be protected. Babies conceived at 
the end of a RSV season may have lower antibody titers due 
to a natural decline of antibodies during the year and thus 
might be more susceptible to RSV disease at the time of 
birth [57] A recent study from Stensballe, et al. (2009) [56] 
showed a temporal association of cord- blood RSV antibody 
levels and rate of hospitalization for RSV in infants under 6 
months of age in Denmark. The incidence of RSV 
hospitalization increased when RSV antibody titers (to the 
log base 2) declined below 7.5, and the RSV epidemic 
peaked shortly after the nadir of the mean antibody level 
Living at Altitude 
  An analysis comparing hospitalization rates for children 
at 3 altitude categories (<1500 m; 1500–2500 m; and >2500 
m) found that infants living at altitudes higher than 2500 m 
were 33% more likely to be hospitalized (relative risk [RR]: 
1.30; P <.018) than those at moderate altitudes, with 1- to 4-
year-old children exhibiting an 80% increase in their 
hospitalization rates (RR: 1.80; P <.001) [58]. Altitude can 
have numerous respiratory effects including lower oxygen 
saturation values, impaired ciliary activity, and hypoxia-
related pulmonary vasoconstriction.  
  A summary of the host related risk factors of RSV is 
displayed in Table 5. 
RISK FACTORS FOR ACQUISITION OF RSV 
Birth before or during RSV Season 
  As mentioned above birth during the first half of the   
RSV season is a risk factor for RSV LRTI requiring 
hospitalization. One aspect is that birth shortly before and 
early after onset of RSV season results in a longer exposure 
period to RSV at a very young age. Another aspect is the fact 
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variation with lower levels within the first half of the RSV 
season due to the fact that mothers have not been exposed  
to RSV for a longer time period. In the Canadian PICNIC 
study [41] the logistic regression analysis showed that   
birth between November and January was one of the five 
independent predictors for the increased risk of RSV 
hospitalization. This data was also confirmed by the Munich 
RSV Study Group [19] Risk factor analysis revealed that 
discharge between October and December was associated 
with a higher risk for RSV hospitalization (OR 2.1;   
0,99- 4,4; P=0,05). The two Spanish FLIP and FLIP- 2 
studies, [38, 39] however, demonstrated that infants with   
a chronological age below 3 months or less at onset of   
RSV season were at higher risk for RSV hospitalization. 
Discharge from the NICU during RSV season was not a 
single significant risk factor. 
Day Care Attendance/ Older Siblings in School or   
Day-Care 
  In the past the attendance of infants and young children 
in a child care setting or a day care group was regarded as a 
significant risk factor for acquisition of LRTI. Henderson,  
et al. (1979) [50] already described that nearly all 103 
healthy children, who did not have prior exposure to RSV, 
became infected in a day- care setting during a 10- year time 
period. Several further studies confirmed this association 
[37] Liese, et al. [19] from the Munich RSV Study Group 
Table 5.  Host Related Risk Factors for RSV Infection 
Risk Factors  PICNIC Study (2004) [16]
 
33- 35 GA n=1758 
FLIP Study (2004) [48] 
33- 35 GA n= 186 
FLIP- 2 Study (2008) [17] 
33-35 GA n= 202 
Other Studies 
Age < 6 months at 
the beginning of 
the RSV season  
not performed  Age < 10 weeks 
OR 3.75 (2.59- 5.45);  
P= 0.0 
Age < 10 weeks 
OR 2.99 (2.23- 4.01);  
P= 2.11*E 
-13 
Law, et al. (2003) [46] 
 
Multiple Birth  not performed  N= 64 (34.4%) 
P= 0.761  
N= 76 (37.6%) 
P=0.083 
Simoes, et al. (1993) [49]
 
Resch, et al. (2005) [15] 
Male Sex  OR 1.91 (1.10-3.31);  
P= 0.02 
N= 117 (62.9%);  
P= 0.057 
N= 121 (59.9%);  
P= 0.083 
 
Low socioeconomic 
status and parental 
education 
not performed  No school or primary:  
N=60 (32.3%) 
High school or university:  
N= 126 (67,8%) 
not performed  Jansson, et al. (2002) [51] 
Anderson, et al. (1988) [52]
 
Mc Connockie (1986) [53]
 
Holberg, et al. (1991) [54] 
Crowded living 
conditions/siblings 
> 5 individuals in the home 
OR 1.69 (0.93-3.10);  
P= 0.088 
Preschool age siblings 
OR 2.76 (1.51-5.03);  
P= 0.001 
> 4 residents and visitors 
OR 1.91 (1.19-3.07); P= 0.0074 
School age siblings  1 
OR 2.85 (1.88-4.33); P= 9.4*E 
-7 
> 4 residents and visitors 
OR 1.37 (0.85-2.20);  
P= 0.238 
School age siblings/day care 
attendance 
OR 2.04 (1.53-2.74);  
P= 1.47*E 
-6 
Liese, et al. (2003) [25] 
Maternal smoking 
and indoor smoke 
pollution 
 2 smokers in the 
household  
OR 1.71 (0.97-3.00);  
P= 0.064 
Tobacco smoke at home 
OR 0.95 (0.66-1.36); P= 0.859 
Mother smoking 
OR 1.49 (1.01-2.18); P= 0.055 
 2 smokers 
OR 1.41 (0.92-2.14); P = 0.146 
Tobacco smoking during 
pregnancy 
OR 1.61(1.16-2.25); P= 0.0044 
 
Malnutrition/ 
Small for 
gestational age 
OR 2.19 (1.14-4.22);  
P= 0.019 
not performed  not performed   
Family history of 
atopy of asthma 
OR 0.42 (0.18-0.996); 
P=0.049 
Family history of wheezing 
OR 1.90 (1.19-3.01); P= 0.0068 
Family history of wheezing 
OR 1.22 (0.89-1.66); P= 0.236 
 
Low cord serum 
antibody titers 
not performed  not performed  not performed  Stensballe, et al. (2009) [56]
 
Stensballe, et al. (2003) [57] 
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found that the presence of siblings in day-care attendance 
increased the risk factor for RSV rehospitalisation in preterm 
infants 35 weeks gestational age significantly, whereas day-
care attendance of the child itself was not a significant risk 
factor. In the Canadian PICNIC study [41] day-care-
attendance of children was the single greatest risk factor in 
preterm infants born at a gestational age of 33- 35 weeks, 
whereas the two Spanish studies- FLIP and FLIP-2 study 
[38,39] revealed no significant association between RSV 
hospitalization and day- care attendance in this age group. 
This was partly explained by the limited utilization of day-
care centres in the study population (<5%).  
Lack of Breast Feeding 
  The role of breast-feeding in preventing RSV disease and 
hospitalization for RSV is undisputed. However data about 
the specific protective effect of breast- feeding on RSV 
infection are conflicting. The reason for its protective effect 
is attributed to RSV- IgA and lactoferrin in the breast milk as 
well as to the fact that breast milk promotes maturation 
probably through the influence of prolactin. The Spanish 
FLIP- Study [38] found breast feeding for >2 months 
protective against RSV hospitalization whereas the FLIP-2 
Study [39]
  did not show a protective effect against RSV. 
Again in the Canadian PICNIC – Study [41] absence of 
breast feeding was not found to be an independent predictor 
for RSV- infection. However, some studies indicate that the 
absence of breast-feeding in combination with other risk 
factors like crowding, passive smoke exposure or low 
socioeconomic status significantly increases the risk for 
development of RSV LRTI [37].  
  A summary of risk factors for acquisition of RSV is 
displayed in Table 6. 
MODELS FOR PREDICTING RSV IN THE LATE 
PRETERM INFANTS 
  Given the high cost of RSV prophylaxis, especially for 
the large population of late preterm infants, an algorithm that 
could identify high-risk infants with significant specificity 
and sensitivity could support the evidence base for 
recommendations for treatment of this group. Since the AAP 
had already made broad recommendations for prophylaxis of 
children in the 33-35 wGA group, we aimed to develop   
an European model for predicting which premature infants 
33 to 35 weeks gestational age were at highest risk for 
hospitalization. Initially we used data from Spain and 
Germany [58]
 to develop the model then we validated the 
scoring system using studies from Denmark [59], France 
[60] and Italy[61]. 
  The model assigns individual weights to the 7 most 
predictive factors from the FLIP study: birth ±10 weeks from 
the beginning of the RSV season; birth weight; breast fed 2 
or fewer months; number of siblings aged 2 years or older; 
number of family members with atopy; number of family 
members with wheezing; and sex [59,60,61,62]. In the 
original study, information on these 7 factors examined by 
discriminant function analysis resulted in a diagnostic 
accuracy of 71% when trying to identify premature infants 
hospitalized with RSV. Discriminant function analysis 
optimizes which variables discriminate between two or more 
naturally occurring groups, here RSV-hospitalized vs. non-
RSV-hospitalized premature infants 33 to 35 wGA. The 
summary diagnostic accuracies of the initial model derived 
from the FLIP 2 study as well as the validations from 
Munich, France, Italy and Denmark are presented in Table 7. 
It is currently being implemented in some countries to 
determine the most effective application of palivizumab in 
this population.  
 Sampalis, et al. [63] also developed a scoring system, 
based on a logistic regression model, using prospectively 
collected data on 1758 Canadian infants 33-35wGA, 66 of 
whom were hospitalized,and validated using the FLIP 2 
study data. The risk score also included 7 risk factors and 
cutoff scores of 0-48, 49-64, and 65- 100 for low-, moderate-, 
and high-risk subjects, respectively. The sensitivity and 
specificity for predicting RSV hospitalization were 68% and 
72%, respectively, with the Canadian data and 62% and 
Table 6.  Risk Factors for RSV Acquisition  
Risk Factors  PICNIC Study (2004) [16]
 
33- 35 GA n=1758 
FLIP Study (2004) [48] 
33- 35 GA n= 189 
FLIP- 2 Study (2008) [17] 
33-35 GA n= 202 
Other Studies 
Birth before or 
during RSV season 
OR 4.88 (2.57-9.29);  
P= <0.001 
Chronological age at start of  
RSV season  10 wk 
OR 3.95 (2.65-5.90);  
P= 3.2*E
-11 
Chronological age at start of RSV season  
 10 wk 
OR 2.99 (2.23-4.01);  
P= 2.11*E
-13 
Liese, et al. (2003) [25] 
Day care attendance 
/older siblings in 
school or day care 
OR 12.32 (2.56-59.34);  
P= 0.002 
School age siblings ( 1) 
OR 2.85 (1.88-4.33);  
P= 9.4*E
-7  
School age siblings or day care attendance 
OR 2.04 (1.53-2.74);  
P= 1.47*E 
-6 
 
Lack of breast 
feeding 
OR 1.75 (1.08-2.82);  
P= 0.02 
Breast feeding 2 months 
OR 3.26 (1.96-5.42);  
P= 5.5*E
-6 
not significant   
OR Odds ratio; P p-value, N number, GA gestational age. 152    The Open Microbiology Journal, 2011, Volume 5  Sommer et al. 
66%, respectively, with the FLIP data set. In a single center 
study using this scoring tool [64], in 430 children over 3 
seasons, 346 infants in the low risk group received no 
prophylaxis, while 78 of 84 moderate to high risk infants 
received prophylaxis. None of the latter group was 
hospitalized, but 5/346 low risk group infants were 
hospitalized. Thus it would appear that the Canadian scoring 
tool identified most high risk babies for prophylaxis since the 
overall rate of hospitalization was 5/430 (1.2%) compared   
to the rate of 66/1758 (3.7%) [65]
 in the multicenter study  
of un-prophylaxed Canadian infants. Validation of the 
European Risk Factor Scoring Tool is being undertaken in 
Holland and other European countries. 
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